✉news WorldEU Politics first seen 10 h ago, last 54 min ago, peak #11

Hansoh lung cancer drug loses EU approval after AstraZeneca challenge

Original: Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge

Hansoh Pharmaceutical's copy of AstraZeneca's lung cancer drug Tagrisso has lost its European Union approval following a successful legal challenge by AstraZeneca. The decision removes the Chinese drugmaker's competing osimertinib-like therapy from the EU market and represents a significant win for AstraZeneca in defending its blockbuster oncology franchise.

Why now: AstraZeneca's legal victory blocks a major Chinese rival to one of its top-selling cancer drugs in Europe.

Hansoh PharmaceuticalAstraZenecaEuropean UnionTagrisso

Open on news →

Rank over time, top of the chart is #1. 6 snapshots from 10 h ago to 54 min ago.

Evidence

• Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge · fiercepharma.com

API: https://socialmediatrends-api.osmike.com/v1/trends/503879